Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies

Nikita Pozdeyev, Minjae Yoo, Ryan Mackie, Rebecca E. Schweppe, Aik Choon Tan, Bryan R. Haugen

Research output: Contribution to journalArticlepeer-review

37 Citations (Scopus)


The consistency of in vitro drug sensitivity data is of key importance for cancer pharmacogenomics. Previous attempts to correlate drug sensitivities from the large pharmacogenomics databases, such as the Cancer Cell Line Encyclopedia (CCLE) and the Genomics of Drug Sensitivity in Cancer (GDSC), have produced discordant results. We developed a new drug sensitivity metric, the area under the dose response curve adjusted for the range of tested drug concentrations, which allows integration of heterogeneous drug sensitivity data from the CCLE, the GDSC, and the Cancer Therapeutics Response Portal (CTRP). We show that there is moderate to good agreement of drug sensitivity data for many targeted therapies, particularly kinase inhibitors. The results of this largest cancer cell line drug sensitivity data analysis to date are accessible through the online portal, which serves as a platform for high power pharmacogenomics analysis.

Original languageEnglish
Pages (from-to)51619-51625
Number of pages7
Issue number32
Publication statusPublished - 2016 Aug 1


  • Cancer
  • Cell line
  • Database integration
  • Drug sensitivity
  • Pharmacogenomics

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies'. Together they form a unique fingerprint.

Cite this